Published in:
01-01-2015 | Original Article
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
Authors:
Tsutomu Kobayashi, Junya Kuroda, Shin-ichi Fuchida, Hitomi Kaneko, Hideo Yagi, Hirohiko Shibayama, Hirokazu Tanaka, Satoru Kosugi, Nobuhiko Uoshima, Masayuki Kobayashi, Yoko Adachi, Kensuke Ohta, Kazuyoshi Ishii, Hitoji Uchiyama, Mitsuhiro Matsuda, Eiji Nakatani, Mitsuru Tsudo, Chihiro Shimazaki, Akifumi Takaori-Kondo, Shosaku Nomura, Itaru Matsumura, Masafumi Taniwaki, Yuzuru Kanakura, KMF investigators
Published in:
International Journal of Hematology
|
Issue 1/2015
Login to get access
Abstract
We retrospectively investigated the prognostic factor of lenalidomide plus low-dose dexamethasone (Rd) in Japanese patients with refractory or relapsed multiple myeloma (RRMM) registered in the Kansai Myeloma Forum from January 2006 to December 2013. A total of 140 patients were analyzed. The median age was 66 years. The overall response rate was 68.6 %, including 33.1 % with a better than very good partial response. At 13.0 months median follow-up, the median overall survival (OS) and progression-free survival (PFS) were 34.2 and 17.0 months, respectively. In univariate analyses, patients with one or two prior therapies had significantly longer OS (41.2 vs. 21.5 months; P = 0.002) and PFS (29.0 vs. 13.0 months; P = 0.006) than patients treated with three or more prior therapies. Prior use of thalidomide was associated with significantly shorter PFS (19.0 vs. 16.0 months; P = 0.045). The prior use of bortezomib or high-dose therapy with stem cell transplantation, and the International Staging System had no impact on long-term outcome. Multivariate analysis showed that only the number of prior therapies was a significant predictor of both OS and PFS. Our findings suggest that greater benefit may occur when Rd therapy is used at the first or second relapse in RRMM.